News

Filter

Current filters:

EisaiPharmaceutical

1 to 9 of 207 results

First launch for Eisai’s Lenvima, in the USA

First launch for Eisai’s Lenvima, in the USA

03-03-2015

The US subsidiary of Japanese pharma major Eisai has now launched its in-house developed novel anticancer…

EisailenvatinibLenvimaMarkets & MarketingOncologyPharmaceuticalRare diseases

UPDATE: FDA approves Eisai’s Lenvima for a type of thyroid cancer and expands use of Banzel

UPDATE: FDA approves Eisai’s Lenvima for a type of thyroid cancer and expands use of Banzel

14-02-2015

The US Food and Drug Administration on Friday granted approval for Japanese pharma major Eisai’s Lenvima…

BanzelEisailenvatinibLenvimaNeurologicalOncologyPharmaceuticalRare diseasesRegulationUSA

Eisai's lenvatinib shows statistically-significant progression-free survival in Ph III trial

Eisai's lenvatinib shows statistically-significant progression-free survival in Ph III trial

13-02-2015

Japanese drug major Eisai has published results of its SELECT Phase III study, showing its lenvatinib…

EisaiHealthJapanlenvatinibPharmaceuticalWeakness

Helsinn grants Stendhal rights to NEPA in several Latin America countries

02-02-2015

Family-run Swiss oncology specialist Helsinn has granted exclusive rights to Mexico-based Especificos…

AkynzeoEisaiHelsinnLicensingNEPAnetupitantOncologypalonosetronPharmaceuticalSouth AmericaStendhal

German Federal Joint Committee confirms 'considerable' benefit of Eisai's Halaven in breast cancer

German Federal Joint Committee confirms 'considerable' benefit of Eisai's Halaven in breast cancer

23-01-2015

The German Federal Joint Committee has confirmed the ‘considerable’ additional benefit of Japanese…

EisaiGermanyHalavenOncologyPharmaceuticalRegulation

Eisai launches epilepsy treatment Exalief in Russia

Eisai launches epilepsy treatment Exalief in Russia

20-01-2015

Japanese drug major Eisai has announced that epilepsy drug Exalief (eslicarbazepine acetate) will soon…

EisaiExaliefMarkets & MarketingNeurologicalPharmaceuticalRussia

Drugmakers “outraged” at England's Cancer Drugs Fund decision to remove drugs from coverage

Drugmakers “outraged” at England's Cancer Drugs Fund decision to remove drugs from coverage

08-01-2015

England’s Cancer Drugs Fund is overspent and 42 drugs are being reassessed as price caps are brought…

AvastinEisaiHalavenHealthcareJevtanaKadcylaOncologyPharmaceuticalPricingRocheSanofiUKZaltrap

Eisai's Fycompa for refractory partial-onset seizures meets Phase III trial primary endpoint

Eisai's Fycompa for refractory partial-onset seizures meets Phase III trial primary endpoint

05-01-2015

Japanese drug major Eisai has announced a Phase III trial of antiepileptic drug Fycompa (perampanel)…

EisaiFycompaJapanNeurologicalperampanelPharmaceuticalResearch

1 to 9 of 207 results

Back to top